Introduction Takeda Pharmaceutical Co., Ltd. is a global biopharmaceutical company founded in 1781 in Osaka, Japan, committed to improving health worldwide. The company operates in the fields of research, development, manufacturing, and exporting of pharmaceutical drugs with its segments including Prescription Drug, Consumer Healthcare, and Other. Takeda produces and sells pharmaceutical products, over-the-counter drugs, quasi-drugs, reagents, clinical diagnostics, and chemical products. |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 158 |
Monoclonal antibody | 14 |
Proteolysis-targeting chimeras (PROTAC) | 14 |
Enzyme | 11 |
Prophylactic vaccine | 9 |
Target |
Mechanism vWFCP modulators [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. United States |
First Approval Date09 Nov 2023 |
Target |
Mechanism FOLR1 antagonists [+1] |
Active Org. |
Originator Org. |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. United States |
First Approval Date14 Nov 2022 |
Target- |
Mechanism Immunostimulants |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. Indonesia |
First Approval Date22 Aug 2022 |
Start Date30 Sep 2026 |
Sponsor / Collaborator |
Start Date01 Apr 2026 |
Sponsor / Collaborator |
Start Date29 Aug 2025 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Bimatoprost ( Prostanoid receptor ) | Ocular Hypertension More | Approved |
Alpha-1 antitrypsin(Kamada Ltd.) ( A1AT ) | Alpha 1-Antitrypsin Deficiency More | Approved |
Coagulation Factor IX (Recombinant) ( factor IX ) | Hemophilia B More | Approved |
Maribavir ( UL97 ) | Cytomegalovirus Infections More | Approved |
Cefozopran Hydrochloride ( PBPs ) | Bacterial Infections More | Approved |